Nanocarrier-Based Delivery Systems Show Promise in Treating Bone Cancer

Researchers from the Department of Cardiology, Jilin Province FAW General Hospital, have made significant progress in developing nanocarrier-based delivery systems for treating bone cancer. According to a recent study published in IUBMB Life, these systems have improved the bioavailability and targeting of tyrosine kinase inhibitors (TKIs) in bone cancer therapy, reducing systemic toxicity and enabling controlled drug release. The review highlighted various nanocarrier platforms, including liposomes, polymeric nanoparticles, micelles, and dendrimers, which have been systematically evaluated for their efficacy in delivering TKIs for bone cancer therapy.

Key Takeaways:

• The development of nanocarrier-based delivery systems has significantly improved the bioavailability and targeting of TKIs in bone cancer therapy, reducing systemic toxicity and enabling controlled drug release.
• Various nanocarrier platforms, including liposomes, polymeric nanoparticles, micelles, dendrimers, metal- and metal oxide-based nanoparticles, and carbon-based carriers, have been evaluated for their efficacy in delivering TKIs for bone cancer therapy.
• The impact of nanoparticle size on cellular uptake and tumor penetration was examined, with a focus on liposomal and proteinaceous carriers that optimize tumor selectivity while minimizing systemic toxicity.
• Inorganic nanocarriers such as gold, silver, and metal oxides demonstrate potential for multimodal therapeutic and diagnostic applications.
• Despite advances in nanotechnology, challenges including drug resistance, toxicity, and regulatory barriers remain, necessitating ongoing efforts to optimize nanocarrier formulations.
• This comprehensive review provides critical insights into the evolving landscape of nanotechnology-driven TKI delivery strategies aimed at enhancing therapeutic outcomes in bone cancer management.

Statistics:

• The study highlighted the limitations of TKIs in treating bone cancer, including poor bioavailability, systemic toxicity, and inadequate tumor targeting.
• The use of nanotechnology has significantly improved the bioavailability and targeting of TKIs, with advancements in nanocarrier-based delivery systems.
• Liposomal and proteinaceous carriers have been found to optimize tumor selectivity while minimizing systemic toxicity.
• Inorganic nanocarriers, such as gold and silver, demonstrate potential for multimodal therapeutic and diagnostic applications.

Sources:

• IUBMB Life, 2025;77(8)
• NewsRx. Researchers from Department of Cardiology Report on Findings in Cancer Gene Therapy (Progress in Nanocarriers-Based Approaches for the Delivery of Tyrosine Kinase Inhibitors in Bone Cancer: Trends and Prospects). Cancer Weekly. September 2, 2025; p 49
• Wiley, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; IUBMB Life - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-6551)